Zacks small cap research.

On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …Zacks Investment Research is a leading provider of independent investment research with a proven track record of outperforming the market.DIREXION DAILY SMALL CAP BULL 3X SHARES. The Direxion Daily Small Cap Bull 3x Shares seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …

Research and development expenses for the quarter increased to $2.8 million compared to $2.4 million in the 2nd quarter of 2022. The increase was primarily due to preparations for a Phase 2a clinical trial with CC-42344 for pandemic and seasonal influenza A, and preparations for advancing CDI-988’s COVID-19 and norovirus …1. Source: Created by Zacks Small Cap Research Analysts. By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT BALANCE Interim Results On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX …

Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research. BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain …By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT Yesterday Nextech (OTC:NEXCF) preannounced preliminary 2022 revenues of $10.3 million for the year or $1.4 million for Q4 2022. While this looks like a miss compared to our model, it includes $958,822 in revenues eliminated from historical product sales booked in Q1 and Q2 due to reclassifying the pet business as a discontinued

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Nov 18, 2022 · OTC:NEXCF. READ THE FULL NEXCF RESEARCH REPORT. Nextech AR’s (OTC:NEXCF) Q3 report showed a rapid uptake of its AR 3D model subscription business which grew 192% sequentially. It plans to deliver $700,000 worth of models to Amazon (we believe) alone in Q4 and the business continues to thrive. Just as importantly, the company has reduced its ... By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update First Patient Dosed in Phase 1b/2 Trial for Exebacase in Chronic Knee Prosthetic Joint Infections On April 26, 2023, ContraFect Corp. (NASDAQ:CFRX) announced the first patient has been dosed in the Phase 1b/2 clinical trial of exebacase in the setting of a minimally-invasive arthroscopic debridement, antibiotics,John Vandermosten, CFA is currently a Senior Analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 19 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. John is a frequent moderator ...

By M. Marin. NASDAQ:NVX. READ THE FULL NVX RESEARCH REPORT. As Novonix (NASDAQ:NVX), an integrated developer and supplier of high-performance materials, equipment and services for the global lithium-ion battery industry, continues to advance its strategy to develop a U.S.-based lithium-ion battery materials supply chain, …

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO …

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …A new baseball hat tends to be stiff and uncomfortable, and many people prefer the look of an worn-in hat. Fortunately, fading and distressing a baseball cap is quite easy to do. To prepare for the fading process, wet the bill of the hat.Free Weekly Digest. Zacks Small Cap Research covers more than 100 small- and micro-cap companies that are under-followed or under-valued by Wall Street. Our analysts cover all major sectors...That is the S&P 500 performance. So over the last 35 years, the S&P has averaged 10.5%, and the stocks that Zacks ranks as #1 Strong Buy are up 24.3%. So they BEAT THE S&P 500 BY 13.8% on average each year. On top of that, stocks that are ranked as #5 Strong Sell are only up 2.2%, so they’re underperforming the market.When it comes to maintaining the aesthetics and functionality of your wheels, OEM wheel center caps play a crucial role. These small but significant accessories not only add a touch of style to your vehicle’s appearance but also provide ess...By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatmentsThe NELL-1 technology is the centerpiece of what Bone Biologics (NASDAQ:BBLG) is developing. It was developed by UCLA TDG and Bone holds the exclusive worldwide rights to that technology. NELL-1 has been reviewed positively in over 45 peer reviewed publications demonstrating technological viability. NELL-1 has shown spine fusion effectiveness ...

Jul 31, 2023 · Similar to other regions, penetration into the near 22,000 low risk SCCHN cases is expected to start at 3% and rise to 30% by year six then market share stabilization and declines in 2033 and 2034. The final geography that we include in our DCF model is the UK. According to Cancer Research UK, there are about 12,400 head and neck cancers. May 4, 2023 · First Quarter 2023 Financial and Operational Results. For the quarter ending March 31, 2023, electroCore Inc. (NASDAQ:ECOR) posted revenues of approximately $2.8 million vs. $1.9 million in the prior year quarter. This represents growth of nearly 50%, driven by increases in the VA/DOD segment and commercial revenues augmented by electroCore’s ... Novonix Cathode Materials is also expected to play a key role in the growing demand for batteries. Last month NVX launched a new pilot production facility for cathode materials in a new 35,000-square-foot facility. The facility enables Novonix to demonstrate the feasibility of large-scale production.Forgot your password? Email us at [email protected] for assistance ...By Brad Sorensen, CFA NASDAQ:ONVO READ THE FULL ONVO RESEARCH REPORT Organovo (NASDAQ:ONVO) reported its fiscal 2Q earnings and results were roughly inline with our expectations and illustrate to us that the company continues to progress toward bringing important products to market. Specifically, the company reported: • Earnings of -$0.46 per share, in line with estimates as expenses remained

On January 17 th, electroCore announced preliminary 4Q:22 revenues of $2.5 million, which is ahead of our $2.2 million expectation. For 2022, revenues were $8.5 million, a 57% increase over 2021 levels. Strength in government channels, which produced a 56% increase were surpassed in percentage terms by growth in commercial which saw a …

Net R&D expenses for the third quarter of 2023 were $3.3 million, compared to $3.8 million during the third quarter of 2022. The decrease was primarily due to decreased costs related to the Phase 3 clinical trial and decreased payroll expense, travel, materials, depreciation, and other activities. G&A expenses for the third quarter of 2023 were ...Nov 10, 2023 · LGVN Continues to Show Progress. Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of ... Jan 5, 2023 · By Thomas Kerr, CFA NASDAQ:UXIN READ THE FULL UXIN RESEARCH REPORT On December 30th, Uxin (NASDAQ:UXIN) reported fiscal 2nd quarter operating and financial results for the three-month period ending September 30, 2022. Total revenues increased to $87 million which was a 1.2% increase from the fiscal 1st quarter and a 78.9% increase from the prior year period. Unit volume was 6,050 vehicles in the David Bautz, PhD, Senior Analyst for Zacks Small-Cap Research, with 9 years of direct experience in the securities and investment industry. David’s research articles have been posted extensively on Yahoo Finance News and throughout life sciences social media circles. Prior to joining Zacks in 2014, David was an NRSA postdoctoral fellow ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates In July 2022, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced the first subjects were dosed in two Phase 1/2a clinical trials of ARO-RAGE and ARO-MUC5AC, which are the company’s investigational candidates designed as potential treatmentsOct 31, 2023 · Fund Description. The fund was incepted in May 2000 and is managed by Franklin Advisers. The objective of this fund is long-term capital growth. The fund invests at least 80% of its net assets in ...

Giles Haycock Managing Director (T) 312.265.9351 (M) 312.752.6718 (F) 312.265.9560 (E) [email protected] Twitter: @ZacksSmallCap Steven Ralston, CFA Director of Research

On February 6, 2023, Arrowhead announced financial results for the first quarter of fiscal year 2023 that ended December 31, 2022. The company reported revenue of approximately $62.5 million for the first quarter of fiscal year 2023 compared to approximately $27.4 million for the first quarter of fiscal year 2022.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Small-Cap Research Lisa R. Thompson 312-265-9154 [email protected] scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 January 18, 2022 Preannounces Q4 Revenues of $8.8 Million up 275% Based on a blended enterprise value to sales multiple of its peers of 5.85 times, we believePut on Your Rally Cap, as We Turn the Last Two Inside-Out Do you get the sense that folks were more bullish after last Wednesday's rally than they were after Monday's rally? That's the sense I get. I suppose that is because last week's rug ...Investrade has good news to share - we are providing all customers FREE Snapshot research reports from Zacks Investment Research. There are reports on 4400 ...SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …The winner of a $100,000 lottery prize would have 25 percent, or $25,000, withheld for federal income taxes. In 34 states, the prize would also be subject to state income taxes ranging from 3.4 percent to 10.8 percent, according to Zacks In...Nov 14, 2023 · 11/14/2023 By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it continues to test and research its potential... By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Advancing Multiple Clinical Trials in 2023 ESSA Pharma Inc (NASDAQ:EPIX) is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens’, which specifically target the androgen …Apr 17, 2023 · Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE. 1. Screenshot of interview with Allarity CEO, Jim Cullem. 2.

By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT First Quarter 2022 Results On May 16, 2022, Novan Inc. (NASDAQ: ... SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information …In recent years, the topic of energy prices has become increasingly important for consumers. With rising concerns about affordability and fair pricing, governments around the world have implemented measures to protect consumers from excessi...Forgot your password? Email us at [email protected] for assistance ...By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update AdCom Granted for NurOwn® On March 27, 2023, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that the U.S. Food and Drug Administration (FDA) has granted an Advisory Committee (AdCom) meeting to discuss …Instagram:https://instagram. good defensive stocksbest online prop trading firmsfutures trading for beginnersccldp stock SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting …Zacks Rank N/A An Investment That’s Easy to Swallow Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 September 20, 2021 312-265-9588 / [email protected] ZACKS ESTIMATES Revenue Q1 Q2 Q3 Q4 Year hightower financialgoldman sachs private equity By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT First Quarter 2023 Results MiMedx Group, Inc. (NASDAQ:MDXG) reported first quarter 2023 revenues of $71.7 million, representing a 22% year over year growth rate, surpassing our $64.2 million estimate. Loss from operations was ($3.4) million, …Zacks Rank N/A Third Quarter Update Zacks Small-Cap Research John D. Vandermosten, CFA Sponsored – Impartial – Comprehensive scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 November 15, 2021 312-265-9588 / [email protected] Revenue Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) sc johnson stock price On May 9, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 2022 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. In the last six weeks, Lantern has dosed its first patient in the Phase II Harmonic study, announced receipt of a patent allowance by the USPTO …By Lisa Thompson NASDAQ:GROM Fresh off a December $5.0 million capital raise and reverse split in December, Grom Social Enterprises (NASDAQ:GROM) is poised to capitalize on a number of promising initiatives over the next several months. The company now has 3.2 million in fully diluted shares and trades at a market capitalization …